A Danish digital weight-loss program combining individualized dosing with was linked to substantial weight loss at 64 weeks among participants who remained enrolled.
Evidence
This retrospective eHealth clinic cohort included 2,694 adults with overweight or obesity, with 465 remaining at week 64, where mean weight loss was 16.7% and mean semaglutide dose was 1.08 mg/week.
Caveat
Retention fell from 2,694 participants at baseline to 465 at week 64, so real-world attrition and retrospective app-based data limit how confidently the results apply to all enrollees.
Simplified
AIMS: To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised dosing with intensive behavioural therapy () in adults living with overweight or obesity.
MATERIALS AND METHODS: This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence-based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.
RESULTS: The study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: -17.4 to -16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.
CONCLUSIONS: Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat-to-target approach integrating medical and behavioural obesity management in a digital setting.
TRIAL REGISTRATION: https://osf.io/86kmc/.
Key numbers
16.7%
Mean Weight Loss
Percentage change in body weight at week 64.
98 of 100
Participants Achieving Weight Loss
Proportion achieving ≥5% weight loss.
1.08 mg/week
Mean Dose
Average weekly dose at week 64.
Full Text
We can’t show the full text here under this license.
